VR Logo

Syndax Pharmaceuticals Inc. (SNDX) download report


Healthcare | Biotechnology & Pharma Research

Syndax Pharmaceuticals Inc. (SNDX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

IPO Date: 03-Mar-2016

CEO & Director: Mr. Michael A. Metzger M.B.A.

Pres, Head of R&D and Director: Dr. Briggs W. Morrison M.D.

Listing: NASDAQ: SNDX

Country: United States

Headquarters: Waltham, MA

Website: https://www.syndax.com

Key Facts

Market cap: $1,075.72 Mln

Revenue (TTM): $139.33 Mln

Earnings (TTM): $15.48 Mln

Cash: $410.91 Mln

Total Debt: $21.02 Mln

Insider's Holding: 5.90%

Liquidity: Low

52 Week range: $13.27 - 22.71

Shares outstanding: 56,232,300

10 Years Aggregate:

  • CFO: $-277.20 Mln
  • EBITDA: $-342.47 Mln
  • Net Profit: $-351.60 Mln

Stock Performance

Time Period Syndax Pharmaceuticals (SNDX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-14.53-9.07-17.14
1 month23.25-3.49-4.85
3 months6.31-7.66-12.74
1 Year1.910.09-16.37
3 Years30.0310.197.97
5 Years6.1211.346.33
10 Years--12.0610.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year Syndax Pharmaceuticals (SNDX) S&P Small-Cap 600 S&P BSE Sensex
2021-1.5725.2721.99
2020153.309.5715.75
201997.3020.8614.38
2018-49.01-9.705.87
201722.1811.7327.91